• metastatic, hormone-sensitive prostate cancer 11
• renal cell cancer (RCC)

 

• endocrine therapy
• androgen deprivation therapy (ADT)
• abiraterone plus ADT
• abiraterone plus docetaxel plus ADT
• apalutamide plus ADT
• darolutamide plus doxetaxel plus ADT
• docetaxel plus ADT
• enzalutamide
• enzalutamide plus ADT

• versus all
• vs endocrine therapy
• vs androgen deprivation therapy (ADT)
• vs docetaxel plus ADT

  All patients

• study list
• mapping
• overview
• meta-analysis
• forest plot
• NMA
• excluded

Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)   studies

metastatic, hormone-sensitive prostate cancer, endocrine therapy vs. androgen deprivation therapy (ADT), meta-analysis of study results

No data for this selection

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;